X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (41) 41
female (35) 35
middle aged (34) 34
oncology (31) 31
index medicus (30) 30
aged (28) 28
adult (27) 27
chemotherapy (19) 19
male (19) 19
breast cancer (17) 17
cancer (17) 17
disease-free survival (16) 16
metastasis (16) 16
treatment outcome (16) 16
antineoplastic combined chemotherapy protocols - adverse effects (15) 15
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
care and treatment (14) 14
breast neoplasms - pathology (13) 13
clinical trials (13) 13
aged, 80 and over (12) 12
breast neoplasms - drug therapy (12) 12
drug administration schedule (11) 11
medicine & public health (11) 11
prognosis (10) 10
survival (10) 10
docetaxel (9) 9
neoplasm metastasis (9) 9
patients (9) 9
survival analysis (9) 9
tumors (9) 9
young adult (9) 9
antimitotic agents (7) 7
antineoplastic agents (7) 7
antineoplastic combined chemotherapy protocols - administration & dosage (7) 7
breast neoplasms - mortality (7) 7
colorectal neoplasms - drug therapy (7) 7
fluorouracil - administration & dosage (7) 7
metastases (7) 7
receptor, erbb-2 - metabolism (7) 7
antibodies, monoclonal - therapeutic use (6) 6
antineoplastic agents - therapeutic use (6) 6
breast neoplasms - metabolism (6) 6
cancer therapies (6) 6
chemotherapy, adjuvant (6) 6
colorectal neoplasms - pathology (6) 6
follow-up studies (6) 6
neoplasm staging (6) 6
open-label (6) 6
prospective studies (6) 6
taxoids - administration & dosage (6) 6
trastuzumab (6) 6
bevacizumab (5) 5
cetuximab (5) 5
dose-response relationship, drug (5) 5
drug therapy (5) 5
her2 (5) 5
kaplan-meier estimate (5) 5
medical research (5) 5
mutation (5) 5
surgery (5) 5
therapy (5) 5
1st-line treatment (4) 4
adjuvant chemotherapy (4) 4
analysis (4) 4
anemia (4) 4
antibodies, monoclonal - adverse effects (4) 4
breast neoplasms - genetics (4) 4
breast neoplasms - surgery (4) 4
breast neoplasms - therapy (4) 4
cancer patients (4) 4
colorectal cancer (4) 4
double-blind method (4) 4
epidermal growth factor (4) 4
growth-factor receptor (4) 4
hematology, oncology and palliative medicine (4) 4
leucovorin (4) 4
lung cancer, non-small cell (4) 4
lung neoplasms - drug therapy (4) 4
lung neoplasms - pathology (4) 4
lymphatic metastasis (4) 4
medicine, general & internal (4) 4
metaanalysis (4) 4
organoplatinum compounds - administration & dosage (4) 4
paclitaxel (4) 4
randomized-trial (4) 4
studies (4) 4
survival rate (4) 4
time factors (4) 4
adenocarcinoma (3) 3
age factors (3) 3
angiogenesis inhibitors - administration & dosage (3) 3
antibodies, monoclonal - administration & dosage (3) 3
antineoplastic agents - adverse effects (3) 3
belgium (3) 3
cancer research (3) 3
carcinoma, non-small-cell lung - drug therapy (3) 3
colorectal carcinoma (3) 3
colorectal neoplasms - genetics (3) 3
colorectal neoplasms - mortality (3) 3
combination (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 07/2014, Volume 32, Issue 21, pp. 2240 - 2247
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2010, Volume 28, Issue 31, pp. 4697 - 4705
Purpose Panitumumab, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS), is approved... 
KRAS MUTATIONS | MCRC | ONCOLOGY | STATISTICS | CETUXIMAB PLUS IRINOTECAN | CHEMOTHERAPY CT | OPEN-LABEL | COMBINATION | Leucovorin - administration & dosage | Predictive Value of Tests | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Chemotherapy, Adjuvant | Colorectal Neoplasms - metabolism | Colorectal Neoplasms - mortality | Drug Administration Schedule | Kaplan-Meier Estimate | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Neoplasm Staging | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2013, Volume 369, Issue 11, pp. 1023 - 1034
Patients who have colorectal cancer with RAS mutations in exon 2 are unlikely to respond to EGFR blockers. A retrospective analysis of tumors containing other,... 
SURVIVAL | 1ST-LINE TREATMENT | LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | RANDOMIZED PHASE-III | CETUXIMAB PLUS IRINOTECAN | BRAF | KRAS CODON 12 | FLUOROURACIL | CHEMOTHERAPY | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Membrane Proteins - genetics | Colorectal Neoplasms - genetics | Humans | Antibodies, Monoclonal - therapeutic use | Proto-Oncogene Proteins - genetics | Disease-Free Survival | Fluorouracil - therapeutic use | Neoplasm Metastasis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Colorectal Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Leucovorin - therapeutic use | Mutation | Colorectal Neoplasms - pathology | Genes, ras | Organoplatinum Compounds - therapeutic use | Care and treatment | Dosage and administration | Research | Gene mutations | Panitumumab | Colorectal cancer | Hypothesis testing | Medical research | Statistical analysis | Epidermal growth factor receptors | Colorectal carcinoma | Metastasis | Cancer therapies | Survival | Patients | Metastases | Studies | Hypotheses | Chemotherapy | Epidermal growth factor | Oxaliplatin | Testing laboratories | Medical prognosis | Biomarkers | Deoxyribonucleic acid--DNA | Tumors
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 70, pp. 146 - 155
Journal Article
by Garassino, Marina Chiara and Cho, Byoung-Chul and Kim, Dong-Wan and Kim, Joo-Hang and Kim, Sang-We and Kim, Young-Chul and Mazières, Julien and Vansteenkiste, Johan and Lena, Hervé and Corral Jaime, Jesus and Gray, Jhanelle E and Powderly, John and Chouaid, Christos and Bidoli, Paolo and Wheatley-Price, Paul and Park, Keunchil and Soo, Ross A and Huang, Yifan and Wadsworth, Catherine and Dennis, Phillip A and Rizvi, Naiyer A and Paz-Ares Rodriguez, Luis and Novello, Silvia and Hiret, Sandrine and Schmid, Peter and Laack, Eckart and Califano, Raffaele and Maemondo, Makoto and Chaft, Jamie and Vicente Baz, David and Berghmans, Thierry and Surmont, Veerle and Reck, Martin and Han, Ji-Youn and Holgado Martin, Esther and Belda Iniesta, Cristobal and Oe, Yuichiro and Chella, Antonio and Chopra, Akhil and Robinet, Gilles and Soto Parra, Hector and Thomas, Michael and Cheema, Parneet and Katakami, Nobuyuki and Su, Wu-Chou and Wolf, Juergen and Lee, Jong-Seok and Saka, Hideo and Milella, Michele and Ramos Garcia, Inmaculada and Sibille, Anne and Yokoi, Takashi and Kang, Eun Joo and Atagi, Shinji and Spaeth-Schwalbe, Ernst and Nishio, Makoto and Imamura, Fumio and Gabrail, Nashat and Veillon, Remi and Derijcke, Sofie and Maeda, Tadashi and Zylla, Dylan and Kubiak, Kendra and Santoro, Armando and Uy, Ma. Noemi and Lucien Geater, Sarayut and Italiano, Antoine and Kowalski, Dariusz and Barlesi, Fabrice and Chen, Yuh-Min and Spigel, David and Chewaskulyong, Busyamas and Garcia Gomez, Ramon and Alvarez Alvarez, Rosa and Yang, Chih-Hsin and Hsia, Te-Chun and Denis, Fabrice and Sakai, Hiroshi and Vincent, Mark and Goto, Koichi and Bosch-Barrera, Joaquim and Weiss, Glen and Canon, Jean-Luc and Scholz, Christian and Aglietta, Massimo and Kemmotsu, Hirotsugu and Azuma, Koichi and Bradbury, Penelope and Feld, Ronald and Chachoua, Abraham and Jassem, Jacek and Juergens, Rosalyn and Palmero Sanchez, Ramon and Malcolm, Albert and Vrindavanam, Nandagopal and Kubota, Kaoru and Waller, Cornelius and Waterhouse, David and Coudert, Bruno and Mark, Zsuzsanna and ... and ATLANTIC Investigators
The Lancet Oncology, ISSN 1470-2045, 04/2018, Volume 19, Issue 4, pp. 521 - 536
Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without tyrosine kinase or anaplastic... 
MULTICENTER | METAANALYSIS | NSCLC | ONCOLOGY | RANDOMIZED CONTROLLED-TRIAL | ATEZOLIZUMAB | IMMUNE CHECKPOINT | NIVOLUMAB | MEDI4736 | CLINICAL ACTIVITY | DOCETAXEL | Lung cancer, Non-small cell | Care and treatment
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2009, Volume 27, Issue 36, pp. 6129 - 6134
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. 11554 - 11554
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2006, Volume 24, Issue 36, pp. 5664 - 5671
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 12/2013, Volume 20, Issue S3, pp. 650 - 660
Inflammation is associated with a worse outcome in cancer and neutrophil:lymphocyte ratio (NLR) is a strong prognostic value. In cancer, nonsteroidal... 
Oncology | Medicine & Public Health | Surgical Oncology | Surgery | INTERNATIONAL EXPERT CONSENSUS | NK ACTIVITY | SURGERY | RANDOMIZED CONTROLLED-TRIALS | PREOPERATIVE NEUTROPHIL | PRIMARY THERAPY | INVASION | ONCOLOGY | POSTMASTECTOMY RADIATION | INFLAMMATION | TUMOR-METASTASIS | DAILY ASPIRIN | Prognosis | Prospective Studies | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Lung Neoplasms - pathology | Male | Neoplasm Recurrence, Local - mortality | Breast Neoplasms - therapy | Neoplasm Recurrence, Local - pathology | Neoplasm Metastasis | Carcinoma, Non-Small-Cell Lung - secondary | Carcinoma, Squamous Cell - mortality | Female | Kidney Neoplasms - therapy | Neutrophils - pathology | Neoplasm Recurrence, Local - therapy | Carcinoma, Squamous Cell - therapy | Survival Rate | Combined Modality Therapy | Lung Neoplasms - therapy | Kidney Neoplasms - mortality | Carcinoma, Non-Small-Cell Lung - mortality | Adenocarcinoma - secondary | Carcinoma, Non-Small-Cell Lung - therapy | Lymphocytes - pathology | Adenocarcinoma - therapy | Breast Neoplasms - pathology | Intraoperative Care | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Breast Neoplasms - mortality | Carcinoma, Squamous Cell - secondary | Kidney Neoplasms - pathology | Diclofenac - administration & dosage | Ketorolac - administration & dosage | Neoplasm Staging | Adenocarcinoma - mortality | Usage | Nonsteroidal anti-inflammatory drugs | Lymphocytes
Journal Article
Journal Article